Pharma / Clinical Trials
Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials
Sanofi and Regeneron's investigational drug, itepekimab, designed for chronic obstructive pulmonary disease (COPD), has yielded mixed outcomes in its Phase 3 clinical trials. While one study (AERIFY-1) achieved its primary endpoint, a paral...